Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Diabetic Macular Edema Dme Epidemiology Forecast

DelveInsight’s ‘Diabetic Macular Edema (DME)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted DME epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

DME Understanding

DME is triggered by Diabetic Retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries. DR is caused by long-term damage to the retina’s small blood vessels. The leakage of fluid into the retina may lead to swelling of the surrounding tissue, including the macula. If left untreated, fluid can leak into the macula’s center, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. The definition of clinically significant macular edema (CSME) is the most significant outcome of the Early Treatment Diabetic Retinopathy Study (ETDRS); it established a method for classifying and diagnosing DME and determining when treatment is required. Previously, DME was defined as CSME or not, and focal laser treatment was initiated only for CSME. Then, DME was subcategorized into two main categories: focal diabetic macular edema (fDME) and diffuse diabetic macular edema (dDME). DME diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as a clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected. Apart from this, tests that help in the diagnosis of DME are visual acuity, refractive error examination, fluorescein angiography (FA), optical coherence tomography (OCT) scan, pupil examination, slit-lamp examination, and retinal examination. However, if the diagnosis is delayed or the condition is left untreated, complications can arise and may even permanently impair the vision.

Epidemiology Perspective by DelveInsight

The DME epidemiology division provides the insights about historical and current DME patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

In 2020, the overall prevalent cases of DME accessed to be around 1,862,529 in the 7MM, which are expected to grow during the forecast period, i.e., 2021–2030.


The disease epidemiology covered in the report provides historical as well as forecasted DME epidemiology [segmented as Total Prevalent cases of DME, Total Diagnosed Prevalent cases of DME, Gender-specific Diagnosed Prevalent Cases of DME, Age-specific Diagnosed Prevalent Cases of DME, Subgroups-Specific Diagnosed Prevalent Cases of DME and Treated cases of DME] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.

Country Wise- DME Epidemiology

  • In the United States, the total number of prevalent cases of DME were 1,026,346 in 2020 which are expected to increase during the forecast period, i.e., 2021–2030.
  • In 2020, the total prevalent cases of DME were 641,864 in EU-5, which are projected to increased during the forecast period, i.e., 2021–2030.
  • In Japan, the total number of prevalent cases of DME were 194,319 in 2020 which are expected to grow during the forecast period, i.e., 2021–2030.
  • Findings from various secondary studies suggest that DME affects more males as compared to females, and is more prevalent in elderly population. In the 7MM, the gender-specific diagnosed cases of DME were 486,120 for males and 352,018 for females, in 2020. In the 7MM, the age-specific diagnosed prevalent cases of DME were 120,436, 363,767 and 353,935 for the age-groups 18-44, 45-64 and ≥75 year, in 2020.
  • In 2020, 193,979 non-central involved cases of DME and 267,876 central-involved DME cases were observed in the United States.

Scope of the Report

  • The DME report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
  • The DME Report and Model provide an overview of the risk factors and global trends of DME in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of DME in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of DME.
  • The report provides the segmentation of the DME epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the DME epidemiology by diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the DME epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the DME epidemiology by age-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the DME epidemiology by subgroups-specific diagnosed prevalent cases of DME in the 7MM.
  • The report provides the segmentation of the DME epidemiology by treated cases of DME in the 7MM.

Report Highlights

  • 10-Year Forecast of DME epidemiology
  • 7MM Coverage
  • Epidemiology Segmentation

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over DME scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to DME?
  • What are the key findings pertaining to the DME epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
  • What would be the total number of patients of DME across the 7MM during the study period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of DME?

Reasons to buy

The DME Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global DME market
  • Quantify patient populations in the global DME market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for DME therapeutics in each of the markets covered
  • Understand the magnitude of DME population by its severity
  • The DME epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The DME Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Diabetic Macular Edema

3. Epidemiology Forecast Flow

4. Disease Background and Overview

4.1. Introduction

4.2. Signs and Symptoms

4.3. Causes of DME

4.4. Risk factors of DME

4.5. Classification of DME

4.6. Pathophysiology of DME

4.6.1. Inflammation (Leukostasis, Inflammatory Cytokines)

4.6.2. Protein kinase C (PKC) pathway

4.6.3. Advanced glycation endproducts (AGEs) pathway

4.6.4. Polyol (sorbitol) pathway

4.6.5. Hexosamine pathway

4.6.6. Mechanisms acting on the Blood-retinal Barrier (BRB)

4.6.7. Vascular endothelial growth factor (VEGF)

4.6.8. The effects of the VEGF family

4.6.9. Activation and inhibition of the VEGF pathway

4.6.10. The role of VEGF in the pathophysiology of DME

4.6.11. Cytokines as predictors and mediators of DME

4.7. Diagnosis

4.7.1. Diagnostic Guidelines

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Assumptions and Rationale

5.3. Epidemiology Scenario: 7MM

5.3.1. Total Prevalent Cases of DME in the 7MM

5.3.2. Total Diagnosed Prevalent cases of DME in the 7MM

5.3.3. Gender-specific Diagnosed Prevalent Cases of DME in the 7MM

5.3.4. Age-specific Diagnosed Prevalent Cases of DME in the 7MM

5.3.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM

5.3.6. Treated cases of DME in the 7MM

5.4. The United States

5.4.1. Total Prevalent Cases of DME in the United States

5.4.2. Total Diagnosed Prevalent cases of DME in the United States

5.4.3. Gender-specific Diagnosed Prevalent Cases of DME in the United States

5.4.4. Age-specific Diagnosed Prevalent Cases of DME in the United States

5.4.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States

5.4.6. Treated cases of DME in the United States

5.5. EU-5 Epidemiology

5.5.1.. Germany

5.5.1.1. Total Prevalent Cases of DME in Germany

5.5.1.2. Total Diagnosed Prevalent cases of DME in Germany

5.5.1.3. Gender-specific Diagnosed Prevalent Cases of DME in Germany

5.5.1.4. Age-specific Diagnosed Prevalent Cases of DME in Germany

5.5.1.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany

5.5.1.6. Treated cases of DME in Germany

5.5.2. France

5.5.2.1. Total Prevalent Cases of DME in France

5.5.2.2. Total Diagnosed Prevalent cases of DME in France

5.5.2.3. Gender-specific Diagnosed Prevalent Cases of DME in France

5.5.2.4. Age-specific Diagnosed Prevalent Cases of DME in France

5.5.2.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in France

5.5.2.6. Treated cases of DME in France

5.5.3. Italy

5.5.3.1. Total Prevalent Cases of DME in Italy

5.5.3.2. Total Diagnosed Prevalent cases of DME in Italy

5.5.3.3. Gender-specific Diagnosed Prevalent Cases of DME in Italy

5.5.3.4. Age-specific Diagnosed Prevalent Cases of DME in Italy

5.5.3.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy

5.5.3.6. Treated cases of DME in Italy

5.5.4. Spain

5.5.4.1. Total Prevalent Cases of DME in Spain

5.5.4.2. Total Diagnosed Prevalent cases of DME in Spain

5.5.4.3. Gender-specific Diagnosed Prevalent Cases of DME in Spain

5.5.4.4. Age-specific Diagnosed Prevalent Cases of DME in Spain

5.5.4.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain

5.5.4.6. Treated cases of DME in Spain

5.5.5. The United Kingdom

5.5.5.1. Total Prevalent Cases of DME in the United Kingdom

5.5.5.2. Total Diagnosed Prevalent cases of DME in the United Kingdom

5.5.5.3. Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom

5.5.5.4. Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom

5.5.5.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom

5.5.5.6. Treated cases of DME in the United Kingdom

5.6. Japan Epidemiology

5.6.1. Total Prevalent Cases of DME in Japan

5.6.2. Total Diagnosed Prevalent cases of DME in Japan

5.6.3. Gender-specific Diagnosed Prevalent Cases of DME in Japan

5.6.4. Age-specific Diagnosed Prevalent Cases of DME in Japan

5.6.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan

5.6.6. Treated cases of DME in Japan

6. Appendix

6.1. Bibliography

6.2. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Table

Table 1: Summary of DME; Epidemiology, and Key Events (2018–2030)

Table 2: Difference between normal and DR affected eye

Table 3: Causes of Macular Edema

Table 4: International Clinical DME Disease Severity Scale

Table 5: Clinically Significant Macular Edema

Table 6: Visual Acuity Test

Table 7: Slit-lamp examination

Table 8: Indirect ophthalmoscopy

Table 9: Laser treatments in DME

Table 10: DME Treatment Potential Side Effects

Table 11: Total Prevalent Cases of DME in the 7MM, In Thousands (2018–2030)

Table 12: Total Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Table 13: Gender-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Table 14: Age-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Table 15: Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Table 16: Treated Cases of DME in the 7MM (2018–2030)

Table 17: Total Prevalent Cases of DME in the United States (2018–2030)

Table 18: Total Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Table 19: Gender-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Table 20: Age-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Table 21: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Table 22: Treated Cases of DME in the United States (2018–2030)

Table 23: Total Prevalent Cases of DME in Germany (2018–2030)

Table 24: Total Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Table 25: Gender-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Table 26: Age-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Table 27: Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Table 28: Treated Cases of DME in Germany (2018–2030)

Table 29: Total Prevalent Cases of DME in France (2018–2030)

Table 30: Total Diagnosed Prevalent Cases of DME in France (2018–2030)

Table 31: Age-specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Table 32: Subgroups-Specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Table 33: Treated Cases of DME in France (2018–2030)

Table 34: Total Prevalent Cases of DME in Italy (2018–2030)

Table 35: Total Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Table 36: Age-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Table 37: Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Table 38: Treated Cases of DME in Italy (2018–2030)

Table 39: Total Prevalent Cases of DME in Spain (2018–2030)

Table 40: Total Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Table 41: Gender-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Table 42: Age-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Table 43: Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Table 44: Treated Cases of DME in Spain (2018–2030)

Table 45: Total Prevalent Cases of DME in the United Kingdom (2018–2030)

Table 46: Total Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Table 47: Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Table 48: Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Table 49: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Table 50: Treated Cases of DME in the United Kingdom (2018–2030)

Table 51: Total Prevalent Cases of DME in Japan (2018–2030)

Table 52: Total Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Table 53: Gender-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Table 54: Age-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Table 55: Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Table 56: Treated Cases of DME in Japan (2018–2030)

List of Figures

Figure 1: Total Prevalent Cases of DME in the 7MM (2018–2030)

Figure 2: Total Diagnosed Prevalent cases of DME in the 7MM (2018–2030)

Figure 3: Gender-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Figure 4: Age-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Figure 5: Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)

Figure 6: Treated cases of DME in the 7MM (2018–2030)

Figure 7: Total Prevalent Cases of DME in the United States (2018–2030)

Figure 8: Total Diagnosed Prevalent cases of DME in the United States (2018–2030)

Figure 9: Gender-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Figure 10: Age-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Figure 11: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)

Figure 12: Treated cases of DME in the United States (2018–2030)

Figure 13: Total Prevalent Cases of DME in Germany (2018–2030)

Figure 14: Total Diagnosed Prevalent cases of DME in Germany (2018–2030)

Figure 15: Gender-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Figure 16: Age-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Figure 17: Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)

Figure 18: Treated cases of DME in Germany (2018–2030)

Figure 19: Total Prevalent Cases of DME in France (2018–2030)

Figure 20: Total Diagnosed Prevalent cases of DME in France (2018–2030)

Figure 21: ender-specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Figure 22: Gender-specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Figure 23: Age-specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Figure 24: Subgroups-Specific Diagnosed Prevalent Cases of DME in France (2018–2030)

Figure 25: Treated cases of DME in France (2018–2030)

Figure 26: Total Prevalent Cases of DME in Italy (2018–2030)

Figure 27: Total Diagnosed Prevalent cases of DME in Italy (2018–2030)

Figure 28: Gender-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Figure 29: Gender-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Figure 30: Age-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Figure 31: Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)

Figure 32: Treated cases of DME in Italy (2018–2030)

Figure 33: Total Prevalent Cases of DME in Spain (2018–2030)

Figure 34: Total Diagnosed Prevalent cases of DME in Spain (2018–2030)

Figure 35: Gender-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Figure 36: Age-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Figure 37: Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)

Figure 38: Treated cases of DME in Spain (2018–2030)

Figure 39: Total Prevalent Cases of DME in the United Kingdom (2018–2030)

Figure 40: Total Diagnosed Prevalent cases of DME in the United Kingdom (2018–2030)

Figure 41: Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Figure 42: Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Figure 43: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)

Figure 44: Total Prevalent Cases of DME in the United Kingdom (2018–2030)

Figure 45: Total Prevalent Cases of DME in Japan (2018–2030)

Figure 46: Total Diagnosed Prevalent cases of DME in Japan (2018–2030)

Figure 47: Gender-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Figure 48: Age-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Figure 49: Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)

Figure 50: Treated cases of DME in Japan (2018–2030)

Forward to Friend

Need A Quote